Kymera Therapeutics develops oral medicines for immune and inflammatory diseases using targeted protein degradation. It last closed at $121.52 on Nov 17, down 3.44% on the day. The average 12-month price target from 11 analysts is $148.00 (+21.8% from the last close), with a high of $170.00 and a low of $116.00. Analyst consensus is Strong Buy, based on the latest ratings from 11 firms (10 buy, 1 hold, 0 sell). Over the past 90 days StreetAlpha recorded 2 whale options trades in KYMR, 50% of them bullish and 50% bearish. In the past 30 days there were 4 dark pool prints totaling $2.4M, the largest $778K.
Each firm's latest rating on KYMR in the past 90 days
Average 12-month target
$148.00
▲ 21.8% upside
Based on 11 analysts who set a price target on KYMR in the past 90 days. The average target is $148.00, with a high of $170.00 and a low of $116.00, compared with the last close of $121.52.
Low $116.00Avg $148.00High $170.00
Blue marker: last close $121.52
Highest target$170.00
Average target$148.00
Lowest target$116.00
Latest rating changes
BarclaysTarget raised
Nov 2Buy$139 → $170
Truist SecuritiesTarget raised
Oct 30Buy$136 → $150
RBC CapitalTarget raised
Oct 30Hold$115 → $116
BTIGTarget raised
Oct 29Buy$134 → $139
Morgan StanleyMaintained
Oct 27Buy$146
Date
Firm
Action
Rating
Price target
Nov 2
Barclays
Target raised
Buy
$139 → $170
Oct 30
Truist Securities
Target raised
Buy
$136 → $150
Oct 30
RBC Capital
Target raised
Hold
$115 → $116
Oct 29
BTIG
Target raised
Buy
$134 → $139
Oct 27
Morgan Stanley
Maintained
Buy
$146
Loading…
Technical Analysis
KYMR · as of the Nov 17 close · updated after every close
Uptrend
The stock sits between its 20 and 50 day averages. It is 18% above its 200 day average, so the longer trend is still up. Momentum is fading (RSI 48). The nearest support is the Pivot S1 at $118.61, and the nearest resistance the Pivot at $122.23.
Short trendBullish
Long trendBullish
MomentumFading
StretchNormal
VolatilityHigh, 5.4%/day
Key levels
$142.4652 week high+17.2%
$125.13Pivot R1+3.0%
$125.0820 day average+2.9%
$123.00Swing high (Sep 23)+1.2%
$122.23Pivot+0.6%
$121.52Last close
$118.61Pivot S1−2.4%
$117.4050 day average−3.4%
$116.46Swing low (Aug 24)−4.2%
$115.81100 day average−4.7%
$99.94200 day average−17.8%
$62.9152 week low−48.2%
Indicators
RSI (14)
47.80
Middle of its range
Neutral
MACD
3.62
Below its signal line
Bearish
Stochastic
35.9
Middle of its range
Neutral
ADX (14)
29.8
Trending up
Williams %R
-83.3
Oversold below −80, overbought above −20
Oversold
CCI (20)
-25.5
Oversold below −100, overbought above 100
Neutral
Rate of change
−4.4%
Change over 10 sessions
Bearish
ATR (14)
$6.57
Typical daily range, 5.4% of price
MA 10Below
MA 20Below
MA 50Above
MA 100Above
MA 200Above
Rising
Short trendBullish
Long trendNot enough history
MomentumStrong
StretchNormal
VolatilityNormal, 9.7%/day
Key levels
$142.4652 week high+17.2%
$125.13Pivot R1+3.0%
$125.0820 day average+2.9%
$123.00Swing high (Sep 23)+1.2%
$122.23Pivot+0.6%
$121.52Last close
$118.61Pivot S1−2.4%
$117.4050 day average−3.4%
$116.46Swing low (Aug 24)−4.2%
$115.81100 day average−4.7%
$99.94200 day average−17.8%
$62.9152 week low−48.2%
Indicators
RSI (14)
58.24
Middle of its range
Neutral
MACD
8.11
Above its signal line
Bullish
Stochastic
65.2
Middle of its range
Neutral
ADX (14)
32.7
Trending up
Williams %R
-51.4
Oversold below −80, overbought above −20
Neutral
CCI (20)
83.8
Oversold below −100, overbought above 100
Neutral
Rate of change
+5.7%
Change over 10 sessions
Bullish
ATR (14)
$11.73
Typical daily range, 9.7% of price
MA 10Above
MA 20Above
MA 50Above
MA 100Above
MA 200–
What happened before, for KYMR
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how KYMR did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
November seasonalityHow KYMR usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How KYMR has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether KYMR is in one of them and how their past KYMR trades turned out.
Kymera Therapeutics is a biopharmaceutical company based in Watertown, Massachusetts, that develops oral medicines. It uses targeted protein degradation, a method that taps into the body's own cell recycling system to remove proteins that cause disease. Its main focus is immunology, with programs aimed at conditions such as atopic dermatitis and asthma, which are often treated with injections. Its medicines are still in clinical testing and are intended for patients with these conditions.